Hims & Hers Health today announced its plans to introduce at-home lab testing through its platform. The new capability will help identify risk of disease before it develops.
The company has acquired an at-home lab testing facility, Sigmund NJ LLC marketed as Trybe Labs, which will allow Hims & Hers to support at-home blood draws and more comprehensive whole body testing. The acquisition will broaden the company’s ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into clinical categories including low testosterone, perimenopausal and menopausal support.
Using a blood lancet, which eliminates the need for needles or dried blood spot cards, customers will be able to learn more about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. Providers on the platform will then be able to use that information as part of determining a personalized treatment plan most appropriate for their patient. In addition, de-identified lab data will accelerate the company’s AI developments, including MedMatch by Hims & Hers, to get one step closer to delivering an AI-powered healthcare experience that can deliver access to affordable, high-quality care tailored to the individual.
Trybe Labs is located in New Jersey. Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers over the next year.
